Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment

Exclusion Criteria

• •Pregnancy or breastfeeding
• •Younger than 18 years
• •Uses of minoxidil and/or 5-alpha reductase inhibitors (such as finasteride or dutasteride) within 3 months of enrolling in the study
• •History of hair transplantation
• •Use of any cosmetic product aimed at improving or correcting the signs of hair loss within 2 weeks prior to screening
• •Facial cancer (squamous and basal cell carcinoma, melanoma)
• •Hereditary or acquired hematologic/coagulation disorders such as: platelet dysfunction syndrome, critical thrombocytopenia, hypofibrinogenemia, impaired coagulation, drepanocytosis (sickle cell anemia).
• •Hemodynamic instability
• •Acute infection
• •Auto-immune disease such as Hashimoto, rheumatoid arthritis, or lupus (exception: vitiligo and alopecia areata)
• •Malignancy with or without metastatic disease
• •Chemotherapy
• •Dermatological diseases affecting the face (e.g. porphyria)
• •Anticoagulant therapy
• •Patients taking Aspirin or other NSAIDs (Nonsteroidal anti-inflammatory drugs) such as Nurofen, Voltaren, Diclofenac or Naproxen can participate, provided medication is interrupted 7 days before beginning of the treatment
• •Patients taking vitamin E supplements can participate, provided medication is interrupted 14 days before beginning of the treatment